<DOC>
	<DOCNO>NCT01124669</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This research study study biomarkers blood sample patient refractory non-small cell lung cancer previously treat sorafenib tosylate .</brief_summary>
	<brief_title>Biomarkers Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate</brief_title>
	<detailed_description>OBJECTIVES : - To determine mutation rate BRAF , KRAS , EGFR patient non-small cell lung cancer treat sorafenib tosylate protocol ECOG-2501 . - To determine association BRAF , KRAS , EGFR mutation status clinical benefit patient treat regimen . OUTLINE : This multicenter study . DNA isolate archived plasma sample analyze BRAF , KRAS , EGFR mutation .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis refractory nonsmall cell lung cancer Received sorafenib tosylate protocol ECOGE2501 Available blood specimen PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>